{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T04:30:22Z","timestamp":1762835422570,"version":"build-2065373602"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,10]]},"DOI":"10.7759\/cureus.96517","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T04:26:38Z","timestamp":1762835198000},"source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant Radiochemotherapy and Total Neoadjuvant Therapy in the Management of Locally Advanced Rectal Cancer"],"prefix":"10.7759","author":[{"given":"M\u00fccahit","family":"Yigit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyer","family":"Roohani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annika","family":"Kurreck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik P","family":"Modest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Ehret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel RL","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024, 74:12-49. 10.3322\/caac.21820","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512159","article-title":"Total neoadjuvant treatment for locally advanced rectal cancer patients: where do we stand?","volume":"24","author":"Dapr\u00e0 V","year":"2023","unstructured":"Dapr\u00e0 V, Airoldi M, Bartolini M, et al.. Total neoadjuvant treatment for locally advanced rectal cancer patients: where do we stand?. Int J Mol Sci. 2023, 24:10.3390\/ijms241512159","journal-title":"Int J Mol Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial","volume":"22","author":"Bahadoer RR","year":"2021","unstructured":"Bahadoer RR, Dijkstra EA, van Etten B, et al.. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021, 22:29-42. 10.1016\/S1470-2045(20)30555-6","journal-title":"Lancet Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.1836","article-title":"Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO\/ARO\/AIO-94 randomized phase III trial after a median follow-up of 11 years","volume":"30","author":"Sauer R","year":"2012","unstructured":"Sauer R, Liersch T, Merkel S, et al.. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO\/ARO\/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012, 30:1926-33. 10.1200\/JCO.2011.40.1836","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Conroy T","year":"2021","unstructured":"Conroy T, Bosset JF, Etienne PL, et al.. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021, 22:702-15. 10.1016\/S1470-2045(21)00079-6","journal-title":"Lancet Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.05.528","article-title":"Localised rectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"36","author":"Hofheinz RD","year":"2025","unstructured":"Hofheinz RD, Fokas E, Benhaim L, et al.. Localised rectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025, 36:1007-24. 10.1016\/j.annonc.2025.05.528","journal-title":"Ann Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0051","article-title":"Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Benson AB","year":"2022","unstructured":"Benson AB, Venook AP, Al-Hawary MM, et al.. Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022, 20:1139-67. 10.6004\/jnccn.2022.0051","journal-title":"J Natl Compr Canc Netw"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.11691","article-title":"Prognostic significance of clinicopathological and molecular features after neoadjuvant chemoradiotherapy in rectal cancer patients","volume":"33","author":"Cho HJ","year":"2019","unstructured":"Cho HJ, Baek JH, Baek DW, et al.. Prognostic significance of clinicopathological and molecular features after neoadjuvant chemoradiotherapy in rectal cancer patients. In Vivo. 2019, 33:1959-65. 10.21873\/invivo.11691","journal-title":"In Vivo"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-006-0388-x","article-title":"Local staging of rectal cancer: the current role of MRI","volume":"17","author":"Klessen C","year":"2007","unstructured":"Klessen C, Rogalla P, Taupitz M. Local staging of rectal cancer: the current role of MRI. Eur Radiol. 2007, 17:379-89. 10.1007\/s00330-006-0388-x","journal-title":"Eur Radiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1125470","article-title":"Assessing the predictive value of clinical factors to pathological complete response for locally advanced rectal cancer: an analysis of 124 patients","volume":"13","author":"Zhou C","year":"2023","unstructured":"Zhou C, Wang K, Zhang X, et al.. Assessing the predictive value of clinical factors to pathological complete response for locally advanced rectal cancer: an analysis of 124 patients. Front Oncol. 2023, 13:10.3389\/fonc.2023.1125470","journal-title":"Front Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.16542","article-title":"Positive circumferential resection margin in rectal cancer is a robust predictor of poor long-term prognosis with clinicopathological bias between groups compensated by propensity-score matching analysis","volume":"43","author":"Sugimoto K","year":"2023","unstructured":"Sugimoto K, Takahashi H, Yuki 2nd, et al.. Positive circumferential resection margin in rectal cancer is a robust predictor of poor long-term prognosis with clinicopathological bias between groups compensated by propensity-score matching analysis. Anticancer Res. 2023, 43:3623-30. 10.21873\/anticanres.16542","journal-title":"Anticancer Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/codi.16103","article-title":"The prognostic value of extramural venous invasion in preoperative MRI of rectal cancer patients","volume":"24","author":"Lehtonen TM","year":"2022","unstructured":"Lehtonen TM, Koskenvuo LE, Sepp\u00e4l\u00e4 TT, Lepist\u00f6 AH. The prognostic value of extramural venous invasion in preoperative MRI of rectal cancer patients. Colorectal Dis. 2022, 24:737-46. 10.1111\/codi.16103","journal-title":"Colorectal Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2009.11.011","article-title":"Patterns of local recurrence in rectal cancer; a study of the Dutch TME trial","volume":"36","author":"Kusters M","year":"2010","unstructured":"Kusters M, Marijnen CA, van de Velde CJ, et al.. Patterns of local recurrence in rectal cancer; a study of the Dutch TME trial. Eur J Surg Oncol. 2010, 36:470-6. 10.1016\/j.ejso.2009.11.011","journal-title":"Eur J Surg Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s003840050072","article-title":"Pathological features of rectal cancer after preoperative radiochemotherapy","volume":"12","author":"Dworak O","year":"1997","unstructured":"Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis. 1997, 12:19-23. 10.1007\/s003840050072","journal-title":"Int J Colorectal Dis"},{"key":"ref15","unstructured":"Common terminology criteria for adverse events (CTCAE), version 5.0. (2017). Accessed. February 10, 2024: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00308","article-title":"Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO\/ARO\/AIO-12","volume":"37","author":"Fokas E","year":"2019","unstructured":"Fokas E, Allg\u00e4uer M, Polat B, et al.. Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO\/ARO\/AIO-12. J Clin Oncol. 2019, 37:3212-22. 10.1200\/JCO.19.00308","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2017.05.048","article-title":"Improved metastasis- and disease-free survival with preoperative sequential short-course radiation therapy and FOLFOX chemotherapy for rectal cancer compared with neoadjuvant long-course chemoradiotherapy: results of a matched pair analysis","volume":"99","author":"Markovina S","year":"2017","unstructured":"Markovina S, Youssef F, Roy A, et al.. Improved metastasis- and disease-free survival with preoperative sequential short-course radiation therapy and FOLFOX chemotherapy for rectal cancer compared with neoadjuvant long-course chemoradiotherapy: results of a matched pair analysis. Int J Radiat Oncol Biol Phys. 2017, 99:417-26. 10.1016\/j.ijrobp.2017.05.048","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.02.027","article-title":"Risk and location of distant metastases in patients with locally advanced rectal cancer after total neoadjuvant treatment or chemoradiotherapy in the RAPIDO trial","volume":"185","author":"Bahadoer RR","year":"2023","unstructured":"Bahadoer RR, Hospers GA, Marijnen CA, et al.. Risk and location of distant metastases in patients with locally advanced rectal cancer after total neoadjuvant treatment or chemoradiotherapy in the RAPIDO trial. Eur J Cancer. 2023, 185:139-49. 10.1016\/j.ejca.2023.02.027","journal-title":"Eur J Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000005799","article-title":"Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO trial","volume":"278","author":"Dijkstra EA","year":"2023","unstructured":"Dijkstra EA, Nilsson PJ, Hospers GA, et al.. Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO trial. Ann Surg. 2023, 278:766-72. 10.1097\/SLA.0000000000005799","journal-title":"Ann Surg"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102771","article-title":"Total neoadjuvant treatment using short-course radiotherapy and four CAPOX cycles in locally advanced rectal cancer with high-risk criteria for recurrence: a Swedish nationwide cohort study (LARCT-US)","volume":"75","author":"Glimelius B","year":"2024","unstructured":"Glimelius B, Khan T, Adolfsson K, et al.. Total neoadjuvant treatment using short-course radiotherapy and four CAPOX cycles in locally advanced rectal cancer with high-risk criteria for recurrence: a Swedish nationwide cohort study (LARCT-US). EClinicalMedicine. 2024, 75:102771. 10.1016\/j.eclinm.2024.102771","journal-title":"EClinicalMedicine"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.06.019","article-title":"Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial","volume":"35","author":"Conroy T","year":"2024","unstructured":"Conroy T, Castan F, Etienne PL, et al.. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial. Ann Oncol. 2024, 35:873-81. 10.1016\/j.annonc.2024.06.019","journal-title":"Ann Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2022.109455","article-title":"Clinical outcome after total neoadjuvant treatment (CAO\/ARO\/AIO-12) versus intensified neoadjuvant and adjuvant treatment (CAO\/ARO\/AIO-04) a comparison between two multicenter randomized phase II\/III trials","volume":"179","author":"Diefenhardt M","year":"2023","unstructured":"Diefenhardt M, Fleischmann M, Martin D, et al.. Clinical outcome after total neoadjuvant treatment (CAO\/ARO\/AIO-12) versus intensified neoadjuvant and adjuvant treatment (CAO\/ARO\/AIO-04) a comparison between two multicenter randomized phase II\/III trials. Radiother Oncol. 2023, 179:10.1016\/j.radonc.2022.109455","journal-title":"Radiother Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.5445","article-title":"Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer: long-term results of the CAO\/ARO\/AIO-12 randomized clinical trial","volume":"8","author":"Fokas E","year":"2022","unstructured":"Fokas E, Schlenska-Lange A, Polat B, et al.. Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer: long-term results of the CAO\/ARO\/AIO-12 randomized clinical trial. JAMA Oncol. 2022, 8:10.1001\/jamaoncol.2021.5445","journal-title":"JAMA Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.2394","article-title":"Association of treatment adherence with oncologic outcomes for patients with rectal cancer: a post hoc analysis of the CAO\/ARO\/AIO-04 phase 3 randomized clinical trial","volume":"6","author":"Diefenhardt M","year":"2020","unstructured":"Diefenhardt M, Ludmir EB, Hofheinz RD, Ghadimi M, Minsky BD, R\u00f6del C, Fokas E. Association of treatment adherence with oncologic outcomes for patients with rectal cancer: a post hoc analysis of the CAO\/ARO\/AIO-04 phase 3 randomized clinical trial. JAMA Oncol. 2020, 6:1416-21. 10.1001\/jamaoncol.2020.2394","journal-title":"JAMA Oncol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092567","article-title":"Selecting a TNT schedule in locally advanced rectal cancer: can we predict who actually benefits?","volume":"15","author":"Aschele C","year":"2023","unstructured":"Aschele C, Glynne-Jones R. Selecting a TNT schedule in locally advanced rectal cancer: can we predict who actually benefits?. Cancers (Basel). 2023, 15:10.3390\/cancers15092567","journal-title":"Cancers (Basel)"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.30097","article-title":"Total neoadjuvant therapy vs standard therapy in locally advanced rectal cancer: a systematic review and meta-analysis","volume":"3","author":"Kasi A","year":"2020","unstructured":"Kasi A, Abbasi S, Handa S, Al-Rajabi R, Saeed A, Baranda J, Sun W. Total neoadjuvant therapy vs standard therapy in locally advanced rectal cancer: a systematic review and meta-analysis. JAMA Netw Open. 2020, 3:10.1001\/jamanetworkopen.2020.30097","journal-title":"JAMA Netw Open"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00032","article-title":"Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy","volume":"40","author":"Garcia-Aguilar J","year":"2022","unstructured":"Garcia-Aguilar J, Patil S, Gollub MJ, et al.. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol. 2022, 40:2546-56. 10.1200\/JCO.22.00032","journal-title":"J Clin Oncol"},{"key":"ref28","unstructured":"ClinicalTrials.gov. Identifier NCT04246684, Short-course radiotherapy versus chemoradiotherapy, followed by consolidation chemotherapy, and selective organ preservation for MRI-defined intermediate and high-risk rectal cancer patients (ACO\/ARO\/AIO-18.1). (2023). Accessed: June 15, 2024: https:\/\/www.clinicaltrials.gov\/study\/NCT04246684?term=NCT04246684&rank=1."},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3390\/antiox10091380","article-title":"NRF2 mediates therapeutic resistance to chemoradiation in colorectal cancer through a metabolic switch","volume":"10","author":"O'Cathail SM","year":"2021","unstructured":"O'Cathail SM, Wu CH, Thomas R, Hawkins MA, Maughan TS, Lewis A. NRF2 mediates therapeutic resistance to chemoradiation in colorectal cancer through a metabolic switch. Antioxidants (Basel). 2021, 10:10.3390\/antiox10091380","journal-title":"Antioxidants (Basel)"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0584-2","article-title":"A rectal cancer organoid platform to study individual responses to chemoradiation","volume":"25","author":"Ganesh K","year":"2019","unstructured":"Ganesh K, Wu C, O'Rourke KP, et al.. A rectal cancer organoid platform to study individual responses to chemoradiation. Nat Med. 2019, 25:1607-14. 10.1038\/s41591-019-0584-2","journal-title":"Nat Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.1683","article-title":"Use of total neoadjuvant therapy for locally advanced rectal cancer: initial results from the pembrolizumab arm of a phase 2 randomized clinical trial","volume":"7","author":"Rahma OE","year":"2021","unstructured":"Rahma OE, Yothers G, Hong TS, et al.. Use of total neoadjuvant therapy for locally advanced rectal cancer: initial results from the pembrolizumab arm of a phase 2 randomized clinical trial. JAMA Oncol. 2021, 7:1225-30. 10.1001\/jamaoncol.2021.1683","journal-title":"JAMA Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/415458-neoadjuvant-radiochemotherapy-and-total-neoadjuvant-therapy-in-the-management-of-locally-advanced-rectal-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T04:26:41Z","timestamp":1762835201000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/415458-neoadjuvant-radiochemotherapy-and-total-neoadjuvant-therapy-in-the-management-of-locally-advanced-rectal-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.96517","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,10]]}}}